FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103254456> ?p ?o ?g. }

• W2103254456 endingPage "1002" @default.
• W2103254456 startingPage "995" @default.
• W2103254456 abstract "Purpose: To retrospectively evaluate which dose-volumetric parameters are associated with the risk of ≥ Grade 3 acute esophageal toxicity (AET) in lung cancer patients treated with three-dimensional conformal radiotherapy (3D-CRT). Methods and Materials: One hundred twenty-four lung cancer patients treated curatively with 3D-CRT were retrospectively analyzed. All patients received conventionally fractionated radiotherapy (RT) with median dose of 60 Gy (range, 54–66 Gy) delivered in 30 fractions (range, 27–33 fractions). Thirty-one patients underwent curative surgery before RT. Ninety-two patients received chemotherapy (induction, 18; concurrent ± induction, 74). Acute esophageal toxicity was scored by Radiation Therapy Oncology Group criteria. The parameters analyzed included sex; age; Karnofsky performance score; weight loss; surgery; concurrent chemotherapy; the percentages of organ volume receiving ≥20 Gy (V20), ≥30 Gy (V30), ≥40 Gy (V40), ≥50 Gy (V50), ≥55 Gy (V55), ≥ 58 Gy (V58), ≥60 Gy (V60), and ≥63 Gy (V63); the percent and absolute length of the esophagus irradiated; the maximum and mean dose to the esophagus; and normal tissue complication probability. Results: Of the 124 patients, 15 patients (12.1%) had Grade 3 AET, and 1 (0.8%) patient had Grade 4 AET. There was no fatal Grade 5 AET. In univariate and multivariate logistic regression analyses, concurrent chemotherapy and V60 were significantly associated with the development of severe (≥ Grade 3) AET (p < 0.05). Severe AET was observed in 15 of 74 patients (20.3%) who received concurrent chemotherapy, and in 1 of 50 patients (2.0%) who did not (p = 0.002). Severe AET was observed in 5 of 87 patients (5.7%) with V60 ≤ 30% and in 11 of 37 patients (29.7%) with V60 > 30% (p < 0.001). Among 50 patients who did not receive concurrent chemotherapy, severe AET was observed in 0 of 43 patients (0%) with V60 ≤ 30% and in 1 of 7 patients (14.2%) with V60 > 30% (p = 0.140). Among 74 patients who received concurrent chemotherapy, severe AET was observed in 5 of 44 patients (11.4%) with V60 ≤ 30% and in 10 of 30 patients (33.3%) with V60 > 30% (p = 0.037). Conclusions: Concurrent chemotherapy and V60 were associated with the development of severe AET ≥ Grade 3. For patients being treated with concurrent chemotherapy, V60 is considered to be a useful parameter predicting the risk of severe AET after conventionally fractionated 3D-CRT for lung cancer. Purpose: To retrospectively evaluate which dose-volumetric parameters are associated with the risk of ≥ Grade 3 acute esophageal toxicity (AET) in lung cancer patients treated with three-dimensional conformal radiotherapy (3D-CRT). Methods and Materials: One hundred twenty-four lung cancer patients treated curatively with 3D-CRT were retrospectively analyzed. All patients received conventionally fractionated radiotherapy (RT) with median dose of 60 Gy (range, 54–66 Gy) delivered in 30 fractions (range, 27–33 fractions). Thirty-one patients underwent curative surgery before RT. Ninety-two patients received chemotherapy (induction, 18; concurrent ± induction, 74). Acute esophageal toxicity was scored by Radiation Therapy Oncology Group criteria. The parameters analyzed included sex; age; Karnofsky performance score; weight loss; surgery; concurrent chemotherapy; the percentages of organ volume receiving ≥20 Gy (V20), ≥30 Gy (V30), ≥40 Gy (V40), ≥50 Gy (V50), ≥55 Gy (V55), ≥ 58 Gy (V58), ≥60 Gy (V60), and ≥63 Gy (V63); the percent and absolute length of the esophagus irradiated; the maximum and mean dose to the esophagus; and normal tissue complication probability. Results: Of the 124 patients, 15 patients (12.1%) had Grade 3 AET, and 1 (0.8%) patient had Grade 4 AET. There was no fatal Grade 5 AET. In univariate and multivariate logistic regression analyses, concurrent chemotherapy and V60 were significantly associated with the development of severe (≥ Grade 3) AET (p < 0.05). Severe AET was observed in 15 of 74 patients (20.3%) who received concurrent chemotherapy, and in 1 of 50 patients (2.0%) who did not (p = 0.002). Severe AET was observed in 5 of 87 patients (5.7%) with V60 ≤ 30% and in 11 of 37 patients (29.7%) with V60 > 30% (p < 0.001). Among 50 patients who did not receive concurrent chemotherapy, severe AET was observed in 0 of 43 patients (0%) with V60 ≤ 30% and in 1 of 7 patients (14.2%) with V60 > 30% (p = 0.140). Among 74 patients who received concurrent chemotherapy, severe AET was observed in 5 of 44 patients (11.4%) with V60 ≤ 30% and in 10 of 30 patients (33.3%) with V60 > 30% (p = 0.037). Conclusions: Concurrent chemotherapy and V60 were associated with the development of severe AET ≥ Grade 3. For patients being treated with concurrent chemotherapy, V60 is considered to be a useful parameter predicting the risk of severe AET after conventionally fractionated 3D-CRT for lung cancer." @default.
• W2103254456 created "2016-06-24" @default.
• W2103254456 creator A5000901786 @default.
• W2103254456 creator A5005127397 @default.
• W2103254456 creator A5008985186 @default.
• W2103254456 creator A5022733670 @default.
• W2103254456 creator A5030363363 @default.
• W2103254456 creator A5039770870 @default.
• W2103254456 creator A5050788614 @default.
• W2103254456 creator A5052122266 @default.
• W2103254456 creator A5055974749 @default.
• W2103254456 creator A5072871494 @default.
• W2103254456 creator A5073362212 @default.
• W2103254456 creator A5075150288 @default.
• W2103254456 creator A5086433588 @default.
• W2103254456 date "2005-07-01" @default.
• W2103254456 modified "2023-10-16" @default.
• W2103254456 title "Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy" @default.
• W2103254456 cites W1966669383 @default.
• W2103254456 cites W1977548677 @default.
• W2103254456 cites W1981346821 @default.
• W2103254456 cites W1986851816 @default.
• W2103254456 cites W2011289165 @default.
• W2103254456 cites W2020687877 @default.
• W2103254456 cites W2025959513 @default.
• W2103254456 cites W2030936493 @default.
• W2103254456 cites W2033456044 @default.
• W2103254456 cites W2045724824 @default.
• W2103254456 cites W2078206491 @default.
• W2103254456 cites W2079935011 @default.
• W2103254456 cites W2086224692 @default.
• W2103254456 cites W2090996809 @default.
• W2103254456 cites W2097512974 @default.
• W2103254456 cites W2098507748 @default.
• W2103254456 cites W2106473232 @default.
• W2103254456 cites W2108215214 @default.
• W2103254456 cites W2151900394 @default.
• W2103254456 cites W2155256756 @default.
• W2103254456 cites W2317448174 @default.
• W2103254456 cites W2323020638 @default.
• W2103254456 cites W2413597207 @default.
• W2103254456 doi "https://doi.org/10.1016/j.ijrobp.2004.12.025" @default.
• W2103254456 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15990000" @default.
• W2103254456 hasPublicationYear "2005" @default.
• W2103254456 type Work @default.
• W2103254456 sameAs 2103254456 @default.
• W2103254456 citedByCount "77" @default.
• W2103254456 countsByYear W21032544562012 @default.
• W2103254456 countsByYear W21032544562013 @default.
• W2103254456 countsByYear W21032544562014 @default.
• W2103254456 countsByYear W21032544562015 @default.
• W2103254456 countsByYear W21032544562016 @default.
• W2103254456 countsByYear W21032544562017 @default.
• W2103254456 countsByYear W21032544562018 @default.
• W2103254456 countsByYear W21032544562019 @default.
• W2103254456 countsByYear W21032544562020 @default.
• W2103254456 countsByYear W21032544562021 @default.
• W2103254456 countsByYear W21032544562022 @default.
• W2103254456 countsByYear W21032544562023 @default.
• W2103254456 crossrefType "journal-article" @default.
• W2103254456 hasAuthorship W2103254456A5000901786 @default.
• W2103254456 hasAuthorship W2103254456A5005127397 @default.
• W2103254456 hasAuthorship W2103254456A5008985186 @default.
• W2103254456 hasAuthorship W2103254456A5022733670 @default.
• W2103254456 hasAuthorship W2103254456A5030363363 @default.
• W2103254456 hasAuthorship W2103254456A5039770870 @default.
• W2103254456 hasAuthorship W2103254456A5050788614 @default.
• W2103254456 hasAuthorship W2103254456A5052122266 @default.
• W2103254456 hasAuthorship W2103254456A5055974749 @default.
• W2103254456 hasAuthorship W2103254456A5072871494 @default.
• W2103254456 hasAuthorship W2103254456A5073362212 @default.
• W2103254456 hasAuthorship W2103254456A5075150288 @default.
• W2103254456 hasAuthorship W2103254456A5086433588 @default.
• W2103254456 hasConcept C121608353 @default.
• W2103254456 hasConcept C126322002 @default.
• W2103254456 hasConcept C144301174 @default.
• W2103254456 hasConcept C2776256026 @default.
• W2103254456 hasConcept C2776694085 @default.
• W2103254456 hasConcept C2777819096 @default.
• W2103254456 hasConcept C2779134260 @default.
• W2103254456 hasConcept C2779742542 @default.
• W2103254456 hasConcept C2779920096 @default.
• W2103254456 hasConcept C29730261 @default.
• W2103254456 hasConcept C2989005 @default.
• W2103254456 hasConcept C38180746 @default.
• W2103254456 hasConcept C43270747 @default.
• W2103254456 hasConcept C509974204 @default.
• W2103254456 hasConcept C71924100 @default.
• W2103254456 hasConcept C81182388 @default.
• W2103254456 hasConceptScore W2103254456C121608353 @default.
• W2103254456 hasConceptScore W2103254456C126322002 @default.
• W2103254456 hasConceptScore W2103254456C144301174 @default.
• W2103254456 hasConceptScore W2103254456C2776256026 @default.
• W2103254456 hasConceptScore W2103254456C2776694085 @default.
• W2103254456 hasConceptScore W2103254456C2777819096 @default.
• W2103254456 hasConceptScore W2103254456C2779134260 @default.
• W2103254456 hasConceptScore W2103254456C2779742542 @default.
• W2103254456 hasConceptScore W2103254456C2779920096 @default.

• next